Studies on the pharmacokinetics and bioavailability of fluconazole

The pharmacokinetic profile of oral administration of a single 200 or 150 mg dose of domestic fluconazole and 150 mg of Pfizer's product Diflucan was investigated by HPLC in 8 healthy volunteers. The pharmacokinetic parameters of fluconazole capsules were listed as follows according the sequence of domestic 200, 150 mg and Diflucan 150 mg: T( 1/2 β): 34.55 ± 5.97, 34.76 ± 2.68 and 31.07 ± 2.42 h. T(max): 1.55 ± 0.28, 1.67 ± 0.89 and 1.97 ± 0.44 h. C(max): 4.63 ± 0.33, 3.77 ± 0.53 and 3.92 ± 0.52 mg/L. AUC: 199.54 ± 23.52, 168.24 ± 13.82 and 164.31 ± 14.91 h·mg/L. V/F(c): 32.97 ± 4.36, 31.32 ± 7.67 and 30.12 ± 2.46 L, Cl(s): 1.01 ± 0.11, 0.90 ± 0.07 and 0.92 ± 0.09 L/h. The bioavailability of domestic fluconazole capsule in comparison with Diflucan was 102.87% ± 9.56%.